Overview

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers

Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre, randomized, Phase II study and will be conducted with co-primary objectives of the study are to assess the efficacy of AUR109, as measured by ORR and safety / tolerability at three different dose levels of the study drug in three cancer indications i.e., colorectal, ovarian cancer and renal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Aurigene Discovery Technologies Limited